These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19721197)

  • 21. Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.
    Koufany M; Jouzeau JY; Moulin D
    Biomed Mater Eng; 2014; 24(1 Suppl):81-8. PubMed ID: 24928921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The current role of thiazolidinediones in diabetes management.
    Rizos CV; Kei A; Elisaf MS
    Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
    Niino M
    Mini Rev Med Chem; 2007 Nov; 7(11):1129-35. PubMed ID: 18045216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety issues and prospects for future generations of PPAR modulators.
    Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacological effects of a thiazolidinedione derivative, pioglitazone].
    Ikeda H; Sugiyama Y
    Nihon Rinsho; 2001 Nov; 59(11):2191-4. PubMed ID: 11712406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homocysteine competes for the peroxisome proliferator-activated receptor nuclear receptors.
    Hayden MR
    J Cardiometab Syndr; 2008; 3(1):70-1. PubMed ID: 18326982
    [No Abstract]   [Full Text] [Related]  

  • 27. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PPAR agonists and the metabolic syndrome.
    Staels B
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of PPAR agonists.
    Home P
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S215-9. PubMed ID: 21525458
    [No Abstract]   [Full Text] [Related]  

  • 30. [PPAR receptors: recent data].
    Vidal H
    Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S5-9. PubMed ID: 15959399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pioglitazone: mechanism of action.
    Smith U
    Int J Clin Pract Suppl; 2001 Sep; (121):13-8. PubMed ID: 11594239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The metabolic syndrome: relationship between insulin sensitivity and the role of peroxisome proliferator-activated receptors (PPARs) in saccharide and lipid metabolism.
    Yahia RB; Lichnovská R; Brychta T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):237-41. PubMed ID: 16601762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Lessons Learned after 25 Years of Studies on the Physiological Roles of the Peroxisome Proliferator-activated Receptor].
    Motojima K
    Yakugaku Zasshi; 2015; 135(10):1083-9. PubMed ID: 26423862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [PPARs, metabolic syndrome and cardiac diseases].
    Carvajal K; Hernández-Esquivel Mde L; Moreno-Sánchez R
    Arch Cardiol Mex; 2007; 77 Suppl 4():S4-66-76. PubMed ID: 18938701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.
    Tan CK; Zhuang Y; Wahli W
    Expert Opin Ther Targets; 2017 Mar; 21(3):333-348. PubMed ID: 28092722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
    Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
    Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
    Sugiyama Y; Murase K; Ikeda H
    Nihon Rinsho; 2000 Feb; 58(2):370-5. PubMed ID: 10707560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peroxisome proliferator-activated receptor: effects on nutritional homeostasis, obesity and diabetes mellitus.
    Viana Abranches M; Esteves de Oliveira FC; Bressan J
    Nutr Hosp; 2011; 26(2):271-9. PubMed ID: 21666962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.